INDP
Indaptus Therapeutics Inc
2.50$
+5.5%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Cash Flow
All figures per share in USD.
Tick rows to compare them in a chart (up to 4)
| Line item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -147.60 | -77.44 | -70.52 | -70.56 | -52.12 | -35.37 | -44.12 | -2,279.03 | -2,349.32 | -2,807.56 | -2,806.18 | -1,926.32 | -191.48 | -77.28 | -44.32 | -44.68 | -36.88 | -15.34 | |
| 11.81 | 7.68 | 6.01 | 4.47 | 6.43 | 6.30 | 5.43 | 214.46 | 137.18 | 105.16 | 61.69 | 56.64 | 0.05 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | |
| – | – | – | – | – | – | – | – | – | – | – | 8.25 | 8.06 | 10.34 | 10.02 | 9.89 | 6.90 | 1.41 | |
| – | – | – | – | – | – | – | – | – | – | – | 8.25 | 8.06 | 10.34 | 9.57 | – | – | – | |
| 6.16 | 4.21 | -12.84 | 6.28 | -5.66 | 6.85 | -0.45 | -479.77 | 76.71 | 645.69 | -46.10 | 15.06 | 6.84 | -34.85 | -5.36 | -1.73 | 1.17 | 3.64 | |
| 7.94 | 13.30 | 7.77 | 30.28 | 2.39 | 15.56 | 0.70 | 399.99 | 94.32 | 634.40 | 689.34 | 61.08 | 472.75 | 0.03 | 0.58 | 0.00 | 0.00 | 0.00 | |
| -7.37 | -13.30 | -85.56 | 15.33 | -17.73 | -32.58 | 25.21 | -1,837.59 | 924.46 | -602.18 | -667.94 | -212.89 | 25.79 | 3.06 | -55.67 | 57.13 | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | 16.58 | 66.99 | – | – | – | 0.00 | 5.92 | |
| 153.52 | 114.49 | 205.46 | 39.03 | 39.09 | 96.99 | 44.83 | 9,183.15 | – | 8,081.57 | 2,517.70 | 157.05 | 66.99 | 330.87 | 1.23 | 0.00 | 14.21 | 18.16 | |
| – | – | – | – | – | – | – | 5,066.53 | -1,424.85 | 4,687.94 | -1,015.94 | -1,986.60 | -124.49 | 256.65 | -99.99 | 12.45 | -22.67 | 2.82 | |
| -155.54 | -90.74 | -78.29 | -100.84 | -54.51 | -50.93 | -44.82 | -2,679.02 | -2,443.64 | -3,441.96 | -3,495.51 | -1,987.40 | -191.48 | -77.31 | -44.91 | -44.68 | -36.88 | -15.34 |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.